Journal
EXPERIMENTAL LUNG RESEARCH
Volume 33, Issue 8-9, Pages 459-481Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/01902140701731805
Keywords
lung aspiration; passive antibody; post-exposure treatment; ricin
Categories
Funding
- NCI NIH HHS [R01-CA101234] Funding Source: Medline
- NIAID NIH HHS [R21-AI059476] Funding Source: Medline
- NIEHS NIH HHS [T32-ES07324, ES00260] Funding Source: Medline
Ask authors/readers for more resources
To investigate the effectiveness of passive antibody treatment as post-exposure therapy for ricin, we had developed an oropharyngeal aspiration model for ricin lethal challenge and antibody administration. When polyclonal anti-deglycosylated ricin A-chain antibody (dgA Ab) was administered between 1-18 hr after ricin challenge, all animals survived while delayed treatment to 24 hr resulted in 30% survival. The protective effects of dgA Ab correlated with inhibition of apoptosis in the lungs in vivo and in RAW264.7 macrophage and Jurkat T cells in vitro. In addition, ricin-induced cell cytotoxicity was inhibited by both dgA Ab and RAC18 monoclonal antibody against ricin A-chain. Administration of RAC18 monoclonal antibody at 4, 18, and 24 hr after ricin exposure resulted in 100%, 60% rind 50% protection, respectively, suggesting that the therapeutic window for passive vaccination extended to atleast 24 hr post-ricin. lung challenge.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available